Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Eli Lilly backs U.S. proposal on drug rebates to lower costs

Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.

Read More »

With New CEO MIA, Gilead Reports Tough Q4 and 2018

Gilead Sciences reported earnings per share profits for the 2018 fourth quarter of $1.44 per share, below analysts’ expectations of $1.70. Revenue for the quarter was $5.8 billion, better than Wall Street’s $5.5 billion expectations, but down from $5.949 billion in the same quarter during 2017.

Read More »

Merck’s Keytruda tops $2 billion in Q4 2018 sales

Merck & Co.’s cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates and sending the company’s shares up.

Read More »

Novo Nordisk’s new diabetes drug, outlook lift shares

Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.

Read More »

Takeda’s fiscal third-quarter profit rises 28 percent on strong sales of main drugs

Takeda Pharmaceutical Co. Ltd. posted a 27.9 percent rise in operating profit for the October-December 2018 period, supported by strong sales of the company’s drugs for bowel disease and multiple myeloma.

Read More »

Celgene Q4 2018 profit beats forecast

Celgene Corp. – which is being bought by Bristol-Myers Squibb Co. – reported a better-than-expected fourth-quarter 2018 profit, driven mainly by higher sales of the psoriasis drug Otezla.

Read More »

Roche sees 2019 sales, profit rise despite competition from copies

Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of the Swiss drugmaker’s $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin.

Read More »

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc. reported fourth-quarter 2018 profit that easily surpassed expectations as sales rose and tax expense fell, but competition for the company’s older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Read More »

Novartis 2019 growth outlook leaves investors wanting more

Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.

Read More »

Botox maker Allergan’s 2018 revenue forecast misses estimates, shares drop

Allergan Plc forecast 2019 revenue below expectations on looming competition for some of the company’s top drugs, and shelved plans to sell the women’s health business.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom